Dosage tables, reconstitution guide, cycle structures, synergy research, safety profile, and COA-verified vendor pricing — everything in one place.
The CJC-1295 / Ipamorelin stack combines a GHRH analog (CJC-1295 without DAC / Mod GRF 1-29) with a selective GHRP (Ipamorelin) to produce synergistic growth hormone release. CJC-1295 activates GHRH receptors on pituitary somatotrophs; Ipamorelin activates ghrelin receptors and suppresses somatostatin. The combination addresses both the stimulatory and inhibitory sides of GH regulation simultaneously.
| Property | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Class | GHRH analog (Mod GRF 1-29) | GHRP / ghrelin receptor agonist |
| Length | 29 amino acids | 5 amino acids (pentapeptide) |
| Half-life | ~30 minutes (SubQ) | ~2 hours (SubQ) |
| Peak GH response | ~15–30 min post-injection | ~15–45 min post-injection |
| Primary receptor | GHRH receptor (pituitary) | GHSR-1a (ghrelin receptor) |
| Selectivity | GHRH receptor only | High — minimal cortisol/prolactin effect |
| Route | Subcutaneous injection | Subcutaneous injection |
| Storage | Lyophilized: refrigerate; reconstituted: refrigerate 30 days | Same |
CJC-1295 / Ipamorelin is most commonly researched as a pre-mixed 5mg/5mg vial for convenience, though the compounds can be dosed separately for flexibility.
| Compound | Dose Per Injection | Frequency | Timing |
|---|---|---|---|
| CJC-1295 (no DAC) | 100–300 mcg | 1–3x daily | Fasted, pre-sleep, or post-workout |
| Ipamorelin | 100–300 mcg | 1–3x daily | Same timing as CJC (co-inject) |
| Pre-mixed 5mg/5mg vial | 100–300 mcg each | 1–3x daily | Single injection covers both |
For a 5mg/5mg vial (5mg CJC + 5mg Ipamorelin), reconstitute with 2.5mL bacteriostatic water for a concentration of 2mg/mL of each compound per mL. At a 200mcg per compound dose, inject 0.1mL (10 units on a U100 syringe).
| Vial | BAC Water | Each Compound /mL | Vol per 200mcg |
|---|---|---|---|
| 5mg + 5mg | 2.5mL | 2,000 mcg/mL | 0.10mL (10 units) |
| 5mg + 5mg | 5mL | 1,000 mcg/mL | 0.20mL (20 units) |
GH is naturally released in pulses — the largest during slow-wave sleep. Injecting 30–60 minutes before bed amplifies this peak. Fasted state is also preferred as elevated insulin blunts GH release. Avoid injecting within 1–2 hours of carbohydrate-heavy meals.
Single pre-sleep injection of 200–300mcg each. Minimizes cost, aligns with the largest natural GH pulse, and is sufficient for most GH optimization research goals. Cycle length: 3–6 months continuous or 5 days on / 2 off.
Morning (fasted) + pre-sleep. Increases total GH stimulation across the day. Used in research protocols targeting more aggressive GH optimization or body composition outcomes. Same 200–300mcg per injection per compound.
Morning + post-workout + pre-sleep. The highest frequency used in research — produces the greatest total GH output but also the highest cost. Reserved for short intensive cycles or specific research applications.
GHRP receptors can desensitize with very frequent dosing (3x daily long-term). The 5/2 schedule or periodic breaks are used to maintain receptor sensitivity. Once daily or twice daily protocols with periodic cycling are more sustainable long-term than continuous 3x daily use.
The combination of a GHRH analog and GHRP is one of the best-documented examples of peptide synergy in the literature. Alba et al. and subsequent studies showed that GHRH + GHRP combinations produce GH responses 2–10 times greater than either compound alone, depending on the specific compounds and doses. This synergy is attributed to the dual mechanism: GHRH stimulation at one receptor class, GHRP stimulation at a separate receptor class, plus somatostatin suppression from the GHRP component.
Multiple studies comparing GHRPs found Ipamorelin the most selective — producing robust GH release with minimal elevation of cortisol, ACTH, or prolactin compared to GHRP-6 and GHRP-2. This selectivity, established by Raun et al. (1998) and supported by subsequent work, is the reason Ipamorelin became the GHRP of choice for the standard GH optimization stack.
Extended protocols (3–6 months) produce sustained IGF-1 elevation proportional to the GH response. IGF-1 normalization in GH-deficient subjects is the downstream marker most researchers use to assess protocol efficacy — body composition, sleep quality, and recovery improvements correlate with IGF-1 restoration.
The CJC-1295 / Ipamorelin combination has a considerably cleaner side effect profile than exogenous HGH. Because it stimulates endogenous GH rather than replacing it, GH levels remain within the range the pituitary can produce naturally — avoiding the supraphysiological exposure associated with HGH injection.
COA-verified vendor pricing with promo codes from S1 Research and Tegridy Research.
View Pricing → Dosage Calculator